Cargando…
EGFR外显子20插入突变阳性NSCLC治疗的临床研究进展
Epidermal growth factor receptor (EGFR) exon 20 insertion mutations are the third most prevalent activating EGFR mutation in non-small cell lung cancer (NSCLC), accounting for 5%-12% of all EGFR mutations in NSCLC cases. Patients harboring EGFR exon 20 insertion mutations exhibit similar clinical ch...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9127758/ https://www.ncbi.nlm.nih.gov/pubmed/35599009 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.103.01 |